Hims & Hers Health and Novo Nordisk A/S, key players in the weight-loss pill market, have seen their stock performance impacted despite rapid growth.

An analysis compares Eli Lilly and Company (LLY) and Novo Nordisk A/S (NVO) to determine which pharmaceutical giant is gaining an advantage in the rapidly expanding $100 billion obesity drug market.

European stocks traded steadily near a record high, but early gains were erased by declines in HSBC Holdings Plc and Novo Nordisk A/S.

The primary owner of Novo Nordisk A/S (NVO) plans to open several incubators across Europe dedicated to the development of obesity drugs.

Novo Nordisk A/S held its Q1 earnings call, highlighting key financial results and business performance for the quarter.

Swati Pradhan sees about 12 obesity patients a day at her clinic in southern Mumbai. She expects this number to at least double from this month as Indian drug makers prepare to launch off-patent versions of Novo Nordisk A/S's blockbuster weight.

Novo Nordisk A/S has announced that its drug Sogroya received FDA approval for three new indications.

Eli Lilly and Company's weight-loss pill has secured its initial approval in Europe. Despite this milestone, Novo Nordisk A/S continues to hold a dominant position in the weight-loss drug market.

Several companies, including Oscar Health, Optimum Communications, and Ormat Technologies, have released highlights from their second-quarter earnings calls. These reports provide updates on their financial performance and business operations for the recent quarter.

Jim Cramer has expressed his desire for Novo Nordisk A/S (NYSE:NVO) to focus on market competition with Eli Lilly rather than engaging in legal battles.

Several pharmaceutical companies, including Eli Lilly, Novo Nordisk, and Novartis, are being highlighted as leading investment opportunities in the longevity and anti-aging sector. These companies are recognized for their potential in developing treatments and technologies aimed at extending lifespan and combating aging.

Pharmaceutical company Novo Nordisk A/S has initiated a share repurchase program, signaling a move to return value to shareholders.

Novo Nordisk A/S and Vivtex Corporation have announced a new partnership, details of which were not specified in the headline.

This article analyzes whether Scholar Rock Holding Corporation (SRRK) is in a better position than Novo Nordisk A/S (NVO) following recent setbacks experienced by both companies.

Novo Nordisk A/S Chief Executive Officer Mike Doustdar talks about the company's performance as its popular Wegovy weight-loss pill disappointed investors with sales that failed to live up to the…

An article examines whether Novo Nordisk A/S (NVO) is strengthening its leadership in the weight-loss market with the launch of its oral Wegovy.

Novo Nordisk A/S has announced the commencement of a share repurchase programme, a corporate action typically aimed at returning value to shareholders and influencing stock price.

Novo Nordisk A/S has initiated a share repurchase programme, as reported by Taiwan News.

Morgan Stanley has upgraded Novo Nordisk A/S (NVO) from Underweight to Equal Weight, providing an explanation for the change in its investment rating.